Picropodophyllin (PPP) is a small molecule inhibitor that has gained attention for its anti-cancer properties. It is a natural product derivative of podophyllotoxin, which is an antimitotic agent derived from the roots of the Podophyllum plant. PPP is known to target several proteins involved in cancer cell survival and proliferation, thereby interrupting the signaling pathways that contribute to tumorigenesis.
Chemical name:
(2R)-3,7-Dimethyl-2-(3-methylbut-2-enyl)-4,5,6,7-tetrahydro-2H-indazole-4,7-dione
Molecular formula:
C16H19NO2
Formula weight:
257.33 g/mol
CAS No:
477-47-4
Top ten keywords from Google and synonyms:
Health benefits of this product:
PPP has been found to have potential therapeutic benefits in several types of cancer. Studies have shown that PPP can inhibit the growth and proliferation of cancer cells in vitro and in vivo. The drug has been shown to induce apoptosis, or programmed cell death, in a variety of cancer cells, including breast, ovarian, prostate, and pancreatic cancers. Additionally, PPP has been found to inhibit angiogenesis, the process by which new blood vessels are formed to support tumor growth. This makes it a promising candidate for cancer therapy.
Potential effects:
PPP has been found to have several potential effects on cancer cells. One of the primary mechanisms is through the inhibition of protein kinase B (AKT), which is a key signaling pathway involved in cancer cell survival and proliferation. PPP has also been found to affect mitochondrial metabolism, leading to decreased ATP production and increased reactive oxygen species (ROS) levels, which can contribute to apoptotic cell death. Additionally, PPP has been found to stimulate autophagy, a process that allows cells to recycle damaged organelles and proteins, which can lead to the prevention of tumor formation.
Product mechanism:
PPP works by inhibiting several proteins involved in cancer cell survival and proliferation. One of the main targets of PPP is protein kinase B (AKT), which is a key signaling pathway involved in the regulation of cell survival and proliferation. By inhibiting AKT, PPP can induce apoptosis, or programmed cell death, in cancer cells. Additionally, PPP has been found to affect mitochondrial metabolism, leading to decreased ATP production and increased ROS levels, which can contribute to apoptotic cell death. PPP also stimulates autophagy, which allows cells to recycle damaged organelles and proteins, which can prevent tumor formation.
Safety:
PPP has shown promising results in preclinical studies, but its safety profile in humans has not yet been fully established. Some studies have reported toxic effects of PPP at high concentrations, such as liver injury and bone marrow suppression. Therefore, further research is needed to determine the appropriate dosing and toxicity levels of PPP.
Side effects:
Currently, there are limited data available regarding the side effects of PPP in humans. However, some studies have suggested that high concentrations of PPP may cause liver injury and bone marrow suppression. Additionally, PPP has been found to inhibit angiogenesis, which can lead to impaired wound healing and adverse cardiovascular events.
Dosing information:
There are currently no established guidelines for the dosing of PPP in humans. Doses used in preclinical studies have ranged from 0.01 to 5 μM. Further research is needed to determine the optimal dosing regimen for PPP in humans.
Conclusion:
Picropodophyllin (PPP) is a promising candidate for cancer therapy due to its ability to inhibit several key signaling pathways involved in cancer cell survival and proliferation. The drug has been shown to induce apoptotic cell death and prevent tumor formation in several types of cancer cells. However, its safety profile in humans has not yet been fully established, and further research is needed to determine the appropriate dosing and toxicity levels of PPP. Overall, PPP shows great potential as a targeted therapy for cancer, and future studies may provide valuable insights into its clinical applications
